Market open
Aclaris Therapeutics/$ACRS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Aclaris Therapeutics
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Ticker
$ACRS
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
89
Website
ACRS Metrics
BasicAdvanced
$252M
-
-$0.52
0.12
-
Price and volume
Market cap
$252M
Beta
0.12
52-week high
$4.07
52-week low
$0.95
Average daily volume
929K
Financial strength
Current ratio
7.033
Quick ratio
6.806
Long term debt to equity
1.725
Total debt to equity
1.725
Management effectiveness
Return on assets (TTM)
-19.39%
Return on equity (TTM)
-25.83%
Valuation
Price to revenue (TTM)
6.202
Price to book
1.29
Price to tangible book (TTM)
1.29
Price to free cash flow (TTM)
-9.097
Growth
Revenue change (TTM)
26.35%
Earnings per share change (TTM)
-68.65%
3-year revenue growth (CAGR)
58.19%
3-year earnings per share growth (CAGR)
-30.45%
What the Analysts think about ACRS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Aclaris Therapeutics stock.
ACRS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ACRS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ACRS News
AllArticlesVideos
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy
Benzinga·1 month ago
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aclaris Therapeutics stock?
Aclaris Therapeutics (ACRS) has a market cap of $252M as of January 30, 2025.
What is the P/E ratio for Aclaris Therapeutics stock?
The price to earnings (P/E) ratio for Aclaris Therapeutics (ACRS) stock is 0 as of January 30, 2025.
Does Aclaris Therapeutics stock pay dividends?
No, Aclaris Therapeutics (ACRS) stock does not pay dividends to its shareholders as of January 30, 2025.
When is the next Aclaris Therapeutics dividend payment date?
Aclaris Therapeutics (ACRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Aclaris Therapeutics?
Aclaris Therapeutics (ACRS) has a beta rating of 0.12. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.